Contextualizing Data for Frontline Sacituzumab Govitecan Plus Pembrolizumab in PD-L1+ TNBC

Recent data from the ASCENT-04 trial have generated enthusiasm for combining sacituzumab govitecan, a TROP-2–directed ADC, with pembrolizumab in PD-L1–positive TNBC. The panelists review how this combination aims to build on immunotherapy’s success by pairing it with a potent ADC that delivers targeted chemotherapy directly to tumor cells.

Early findings suggest improved response rates and durability of benefit compared with standard chemoimmunotherapy, potentially redefining the frontline standard. They discuss how the trial’s design and outcomes compare with previous studies like KEYNOTE-355, emphasizing the importance of understanding safety, sequencing, and biomarker-driven patient selection.

The combination appears well-tolerated, though overlapping toxicities such as neutropenia and diarrhea require careful management. Overall, ASCENT-04 represents a promising advance in expanding effective frontline options for PD-L1–positive TNBC, with implications for future immunotherapy-ADC pairings.